Page 46 - AAOMP Meeting 2019

POSTER ABSTRACTS - TUESDAY, JUNE 11, 2019

#43 RENAL CELL CARCINOMA METASTASIS TO THE PAROTID GLAND.
Dr. Roman Carlos (Integra Cancer Institute, Guatemala City), D r. Nasser Said Al Naief (OHSU, School
of Dentistry and School of Medicine), Dr. Juan Pablo Díaz-Molina (U. of Campinas), Dr. Joao Figueira
Scalini (U. of Campinas), Dr. Paul Edwards (Indiana University)
Introduction: Renal cell carcinoma [RCC] is the most common kidney malignancy in adults, representing 3%
of malignancies. The clear cell variant comprises up to 70% of all RCCs. The tumor often exhibits an
unpredictable behavior. While approximately 20-30% of patients present with evidence of metastasis at initial
diagnosis, late metastasis-up to 20 years following curative nephrectomy- is also well documented. We report
an example of late metastasis of a clear cell RCC to the parotid gland 11 years following initial diagnosis and
management. Materials & Methods: A 52 year old female presented with a complaint of 4 month history of
an asymptomatic left parotid swelling. Review of his medical history revealed a previous diagnosis of clear
cell RCC that was managed with total nephrectomy 11 years prior. A CT scan with contrast delineated an
irregular, enhancing 1.2x0.9 cm mass within the left parotid gland. The mass was excised and demonstrated
CD10, RCC and PAX-2-positive malignant epithelial cells with clear cytoplasm and an admixture of compact-
alveolar (nested) and acinar growth patterns in an intricate, arborizing vascular background. Discussion: It has
been reported that 40% to 50% of RCC exhibit distant metastasis. The most common metastatic sites include
lung, regional lymph nodes, liver and bone. Between 14- 16% of RCC patients may develop supraclavicular
metastases, including to thyroid, cervical lymph nodes, paranasal sinuses, tongue, mandible, facial muscles.
larynx and the salivary glands. We describe the clinicopathologic and radiographic features of a metastatic
clear cell RCC to the parotid gland.

#44 REFLECTANCE MEASUREMENTS OF GOLD NANORODS BIO-CONJUGATED TO ANTI-EGFR
MONOCLONAL ANTIBODY DISCRIMINATE BENIGN FROM MALIGNANT SALIVARY GLAND
TUMORS
Dr. Irit Allon (Barzilai University Medical Center Ashkelon and Ben-Gurion University of the Negev),
Dr. Shiran Sudri (Tel- Aviv University), Prof. Dror Fixler (Bar Ilan university), Prof. Abraham Hirshberg
(Tel- Aviv University)
Objective. Epidermal growth factor receptor (EGFR) has been found to bedysregulated in malignant salivary
gland tumors (MSGT) and can be served as anideal target for nanoparticle-based contrast agents using gold
nanoparticles (GNPs)bio-conjugated to anti-EGFR monoclonal antibodies. We aimed at evaluating
thedetection sensitivity of reflection measurements of gold nanorods (GNRs)bio-conjugated to anti-
epidermal growth factor receptor (GNRs- EGFR) monoclonalantibodies in discriminating benign from
MSGT.
Methods. Tissue sections of 20 cases of MSGT and 10 cases of benigntumors were incubated with GNRs-
EGFR and the reflectance spectrum was measuredusing hyperspectral microscopy.
Results. Reflectance intensity was significantly higher in cases of MSGTcompare with those of pleomorphic
adenoma. Add numbers.
Conclusion. The GNRs reflection measurements were able to discriminatebenign from MSGT suggesting an
objective, non-technique-sensitive method thatis not dependent on the qualification of a technician and with
fewer interpretation errors in comparison to what.